The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancerDaniel Hormaechea‐Agulla, Raúl M. Luque, Juan M. Jiménez‐Vacas et al.|The FASEB Journal|2017Cited by 52
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Clinical Cancer Research|2019Cited by 52
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressivenessDaniel Hormaechea‐Agulla, Raúl M. Luque, Manuel D. Gahete et al.|Molecular Cancer|2017Cited by 51
Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarkerDaniel Hormaechea‐Agulla, Raúl M. Luque, Manuel D. Gahete et al.|Cancer Letters|2016Cited by 38
Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumorsSergio Pedraza‐Arévalo, Justo P. Castaño, Emilia Alors‐Pérez et al.|Translational research|2022Cited by 22